foxo4-dri senolytic peptide human trial 2024 The disordered p53 transactivation domain is the target of FOXO4 and the compound CHK2-USP37 axis stabilizes FOXO4 to
CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1]
Pay in 4 interest-free payments of $6.21 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11



